Latest Whitepapers

Genomics, proteomics and microbiomics are all useful tools in complex disease research. However, using these tools alone can risk critical knowledge gaps and leave researchers struggling to predict disease outcomes.

Flow cytometry is a core technique in many immunology labs.. However, extensive immunophenotyping panels can result in overlapping emission peaks, time-consuming compensation and complex data analysis.

Single-use fermenters (SUFs) use disposable sterile plastic bags that don’t require the traditional high-intensity preparation of SS bioreactors, which are expensive and time-consuming processes.

This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.

mRNA-based therapies, from infectious disease vaccines to genetic disorder treatments, are gaining traction. However, mRNA purification methods must evolve beyond traditional precipitation techniques to meet the demands of large-scale therapeutic production.

For a smooth molecule journey from benchtop to clinic you need to make the most informed candidate selection and reduce the risk of failure and complications during development. Our BiacoreTM systems support informed decision-making during the lead candidate selection process. Its technology delivers valuable insights into developability such as manufacturability and safety.

High-fidelity affinity chromatography ligands can support more efficient, cost-effective manufacturing, providing superior yield in a single purification step and accelerating drugs to market.

This whitepaper explores how antibody-based affinity chromatography can reduce the number of process steps, improve yield and increase the purity of your biologic products.

The rapid and accurate identification of microbial contaminants is crucial for quality control in pharmaceutical processes and products. However, until recently, testing labs have relied on time-consuming phenotypic approaches to ensure that safety standards are met.

Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.